An additional therapeutic strategy has been explored with the use of cyclin-dependent kinase (CDK) 4/6 inhibitors, as a synthetic lethal interaction between KRAS oncogenes and CDK4 in NSCLC [83]. Here, KRAS is linked to non-small cell lung carcinoma.